Aim: Recent studies with extended release (ER) niacin in patients receiving intensive
statin treatment with very low levels of low-density lipoprotein cholesterol (LDL-C)
showed no benefit. In HPS2-THRIVE there was a trend for better outcomes in subgroups
with higher baseline LDL-C or apolipoprotein (apo) B. We compared the lipid responses
to ER niacin/ laropiprant in Chinese patients with and without familial hypercholesterolaemia
(FH) to identify if those with higher baseline LDL-C might benefit.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
EAS-0162
Identification
Copyright
© 2015 Published by Elsevier Inc.
